Keywords: Janssen, Johnson & Johnson, Risperdal, Marketing practices, Settlement

Janssen to pay $181 million in Risperdal settlement

Article | 31 August 2012

Print This

US health care giant Johnson & Johnson’s (NYSE: JNJ) Janssen Pharmaceuticals yesterday announced a settlement and consent decree ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in